Tuberous sclerosis complex: molecular pathogenesis, multidisciplinary management and future therapy

Background Tuberous sclerosis complex (TSC) is a rare, autosomal dominant neurocutaneous disorder caused by pathogenic variants in TSC1 or TSC2 , leading to constitutive hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. This dysregulation drives the formation of benign hamartomas across multiple organ systems, including the brain, skin, kidneys, heart, and lungs. TSC exhibits complete penetrance but remarkably variable expressivity, posing significant diagnostic and management challenges. Main body This comprehensive review synthesizes the pathogenesis, clinical manifestations, and therapeutic advancements in TSC. We detail the updated 2021 diagnostic criteria, which prioritize specific neuroimaging and clinical features. The spectrum of neurologic morbidity is explored, focusing on epilepsy affecting up to 90% of patients and TSC-Associated Neuropsychiatric Disorders (TAND), a nearly universal comorbidity encompassing intellectual disability, autism spectrum disorder, and behavioral challenges. We examine the age-dependent evolution of major manifestations, including subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), and lymphangioleiomyomatosis (LAM). The review highlights the paradigm shift driven by mTOR inhibitors (everolimus, sirolimus), whose efficacy in landmark EXIST trials has transformed care for SEGAs, AML, and LAM. We discuss the preventive use of vigabatrin for epilepsy, as evidenced by the EPISTOP trial, and the critical role of lifelong, multidisciplinary surveillance. We also critically appraise limitations of current evidence, including variable efficacy of mTOR inhibition across organ systems, unmet needs in TAND management, and challenges of lifelong therapy. Emerging frontiers, synthetic lethality strategies, genetic medicine (gene augmentation, CRISPR-Cas9, base/prime editing), and AI-driven precision care—are synthesized within a unified therapeutic trajectory. Conclusion The management of TSC has evolved from reactive intervention to proactive, mechanism-driven precision medicine. Despite transformative advances, significant challenges remain, including TAND management, disease heterogeneity, and global care equity. Future horizons are poised to move beyond chronic suppression toward curative strategies, including combinatorial therapies to induce synthetic lethality and pioneering genetic medicine approaches. This review underscores the imperative of integrated, multidisciplinary care to optimize outcomes and quality of life for individuals with TSC throughout their lifespan.

Authors

Institutions

Publication Details

Journal
Frontiers in Neurology
Published
2026-11-12
DOI
https://doi.org/10.3389/fneur.2026.2000365
Primary Topic
Tuberous Sclerosis Complex Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tuberous sclerosis complex: molecular pathogenesis, multidisciplinary management and future therapy

Isah Salim Ahmad, Qiang Zhang, Zhanqi Hu, Zhao Liao et al.
Frontiers in Neurology
Tuberous Sclerosis Complex Research
article

Tuberous sclerosis complex: molecular pathogenesis, multidisciplinary management and future therapy

Isah Salim Ahmad, Qiang Zhang, Zhanqi Hu, Zhao Liao, Tian Yu, Haifeng Wang, Benqing Wu, Jincheng Dai, Xiuqin Chen, Rabiatu Suleiman Bako
article en

Abstract

Background Tuberous sclerosis complex (TSC) is a rare, autosomal dominant neurocutaneous disorder caused by pathogenic variants in TSC1 or TSC2 , leading to constitutive hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. This dysregulation drives the formation of benign hamartomas across multiple organ systems, including the brain, skin, kidneys, heart, and lungs. TSC exhibits complete penetrance but remarkably variable expressivity, posing significant diagnostic and management challenges. Main body This comprehensive review synthesizes the pathogenesis, clinical manifestations, and therapeutic advancements in TSC. We detail the updated 2021 diagnostic criteria, which prioritize specific neuroimaging and clinical features. The spectrum of neurologic morbidity is explored, focusing on epilepsy affecting up to 90% of patients and TSC-Associated Neuropsychiatric Disorders (TAND), a nearly universal comorbidity encompassing intellectual disability, autism spectrum disorder, and behavioral challenges. We examine the age-dependent evolution of major manifestations, including subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), and lymphangioleiomyomatosis (LAM). The review highlights the paradigm shift driven by mTOR inhibitors (everolimus, sirolimus), whose efficacy in landmark EXIST trials has transformed care for SEGAs, AML, and LAM. We discuss the preventive use of vigabatrin for epilepsy, as evidenced by the EPISTOP trial, and the critical role of lifelong, multidisciplinary surveillance. We also critically appraise limitations of current evidence, including variable efficacy of mTOR inhibition across organ systems, unmet needs in TAND management, and challenges of lifelong therapy. Emerging frontiers, synthetic lethality strategies, genetic medicine (gene augmentation, CRISPR-Cas9, base/prime editing), and AI-driven precision care—are synthesized within a unified therapeutic trajectory. Conclusion The management of TSC has evolved from reactive intervention to proactive, mechanism-driven precision medicine. Despite transformative advances, significant challenges remain, including TAND management, disease heterogeneity, and global care equity. Future horizons are poised to move beyond chronic suppression toward curative strategies, including combinatorial therapies to induce synthetic lethality and pioneering genetic medicine approaches. This review underscores the imperative of integrated, multidisciplinary care to optimize outcomes and quality of life for individuals with TSC throughout their lifespan.

Frontiers in NeurologyVol. 17
Chinese Academy of Sciences (CN), Shenzhen Institutes of Advanced Technology (CN), Shenzhen University of Advanced Technology (CN)
Tuberous Sclerosis Complex Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon